Industry Liaison Forum
The International AIDS Society-Industry Liaison Forum (IAS-ILF) is a mechanism to inform and support collaboration and partnership between industry and the IAS. Guided by a strong, multi-stakeholder advisory group, it performs this broad task by regularly providing opportunities for industry to understand the IAS’s interests and priorities, and vice versa, seeking common ground to enhance the impact of our response to HIV and related co-morbidities.
IAS-ILF symposium at INTEREST
Expanding access to viral load monitoring in resource-limited settings
This symposium, held in conjunction with the 8th INTEREST Workshop 2014 in Lusaka, Zambia, provided an occasion to discuss how to expand access to VL monitoring in resource-limited settings (RLS) and to maximize the benefits, in line with the 2013 WHO Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. The session highlighted challenges and solutions in expanding access to VL monitoring. The first two presentations gave an overview of the clinical and financial arguments regarding routine VL monitoring, and the third presentation highlighted laboratory challenges. Following a community perspective to help contextualize this information, a panel discussed solutions to overcome implementation barriers.
The meeting agenda, report and presentations are available for download here.
2013 Annual Report
The IAS-ILF 2013 Annual Report is now available for download.
IAS-ILF Corporate Partners
A list of previous sponsoring industry partners is available here.
3 September 2014
The Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) launches a new round of research grants for 2015
22 August 2014
ViiV Healthcare receives FDA approval for Triumeq
24 July 2014
IAS and ViiV prioritise paediatric HIV research: £1.5 million additional funding from ViiV Healthcare enables the programme expansion
24 July 2014
The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF)
17 July 2014
The Medicines Patent Pool Signs A Record Seven New Sub-Licences to Speed the Availability of Generic HIV Medicines to Developing Countries
13 June 2014
The IAS adds its support to call for Hepatitis B birth dose
27 May 2014
The International AIDS Society announces the appointment of new Executive Director, Owen Ryan
6 march 2014
The International AIDS Society (IAS) announces a new grant of £500,000 from ViiV Healthcare to support its Collaborative Initiative for Paediatric HIV Education and Research (CIPHER)
Articles from previous years are available here